Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

Background In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab
and capecitabine significantly improved overall survival (OS) and progression-free survival …

Background HER2-targeted therapies have substantially improved outcomes for patients
with HER2-positive breast and gastric or gastro-oesophageal junction cancers. Several …

Background Both clinical and genomic data independently predict survival and treatment
response in early-stage HER2-positive breast cancer. Here we present the development …

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of
breast cancers (BC). Approximately 60–70% of HER2+ BC co-express hormone receptors …

Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the
ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown …

HER2-positive breast cancer represents 15%-20% of breast malignancies and is
characterized by an aggressive behavior and high recurrence rates. Anti-HER2-directed …

Simple Summary The breakthrough in developing novel HER2-targeting antibody drug
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …